Development of Chemistry-Based Screening Platform for Access to Mirror-Image Library of Natural Products - Taro Noguchi

Development of Chemistry-Based Screening Platform for Access to Mirror-Image Library of Natural Products (eBook)

(Autor)

eBook Download: PDF
2017 | 1st ed. 2018
XIV, 80 Seiten
Springer Singapore (Verlag)
978-981-10-6623-8 (ISBN)
Systemvoraussetzungen
96,29 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

This thesis mainly describes the development of a screening process for a mirror-image library of chiral natural products. It demonstrates how, by using mirror-image proteins for the screening of available natural products, unavailable mirror-image isomers of natural products can be screened in a mirror process. Moreover, as mirror-image isomers including target proteins and natural products are mainly prepared by means of chemical synthesis, the screening strategy presented here suggests the importance of organic chemistry.

Natural products are commonly used as valuable resources for drug discovery. However, as they are mostly produced as single enantiomeric forms, researchers have tested o

nly natural products bearing one stereochemistry available in nature. As natural products and their enantiomers have identical physicochemical properties and different biological activities, mirror-image isomers of natural products are promising candidates for novel medicinal resources.

In an effort to identify anticancer agents from the mirror-image library, chemical protein syntheses of some target oncoproteins, MDM2, MDMX and Grb2, and their applications to the chemical array screening process were achieved. In the course of this process the NP843 enantiomer, which is the enantiomer of an α-tocopherol derivative, was successfully identified as a novel MDM2-p53 interaction inhibitor. These results clearly show that a mirror-image library of chiral natural products represents an invaluable medicinal resource. Accordingly, the chemistry-based screening strategy described in this thesis will be of great interest to a broad range of chemists involved in natural product, medicinal, and synthetic chemistry.


This thesis mainly describes the development of a screening process for a mirror-image library of chiral natural products. It demonstrates how, by using mirror-image proteins for the screening of available natural products, unavailable mirror-image isomers of natural products can be screened in a mirror process. Moreover, as mirror-image isomers including target proteins and natural products are mainly prepared by means of chemical synthesis, the screening strategy presented here suggests the importance of organic chemistry. Natural products are commonly used as valuable resources for drug discovery. However, as they are mostly produced as single enantiomeric forms, researchers have tested only natural products bearing one stereochemistry available in nature. As natural products and their enantiomers have identical physicochemical properties and different biological activities, mirror-image isomers of natural products are promising candidates for novel medicinal resources. In an effort to identify anticancer agents from the mirror-image library, chemical protein syntheses of some target oncoproteins, MDM2, MDMX and Grb2, and their applications to the chemical array screening process were achieved. In the course of this process the NP843 enantiomer, which is the enantiomer of an a-tocopherol derivative, was successfully identified as a novel MDM2-p53 interaction inhibitor. These results clearly show that a mirror-image library of chiral natural products represents an invaluable medicinal resource. Accordingly, the chemistry-based screening strategy described in this thesis will be of great interest to a broad range of chemists involved in natural product, medicinal, and synthetic chemistry.

Introduction.- Development of a Mirror-image Screening Process by Using Synthetic Proteins.- Synthesis of Grb2 SH2 Domain Proteins for Mirror-image Screening Systems.- Conclusions.

Erscheint lt. Verlag 3.11.2017
Reihe/Serie Springer Theses
Springer Theses
Zusatzinfo XIV, 80 p. 46 illus., 18 illus. in color.
Verlagsort Singapore
Sprache englisch
Themenwelt Medizin / Pharmazie Studium
Naturwissenschaften Biologie Biochemie
Naturwissenschaften Chemie Organische Chemie
Naturwissenschaften Chemie Physikalische Chemie
Technik
Schlagworte Anticancer agents • Mirror-Image Protein Technology • Natural Product-based Drug Discovery • Total Synthesis of Natural Products • Total Synthesis of Proteins
ISBN-10 981-10-6623-X / 981106623X
ISBN-13 978-981-10-6623-8 / 9789811066238
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 4,6 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich

von Donald Voet; Judith G. Voet; Charlotte W. Pratt

eBook Download (2019)
Wiley-VCH Verlag GmbH & Co. KGaA
73,99

von Donald Voet; Judith G. Voet; Charlotte W. Pratt

eBook Download (2019)
Wiley-VCH Verlag GmbH & Co. KGaA
73,99